Healthcare stocks were declining premarket Thursday, with the iShares Biotechnology ETF (IBB) 1% lower and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.
Immix Biopharma (IMMX) shares were up more than 6% after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.
Nanobiotix (NBTX) launched a global follow-on offering of 75 million euros ($87.2 million), the clinical-stage biotechnology company said. Nanobiotix stock was down more than 5% pre-bell.
Relay Therapeutics (RLAY) shares were up more than 10% after the company said it priced a public offering of 22.9 million common shares at $12 each.